Chris Viehbacher

Pharma

Biogen lays out $5.6B to acquire Apellis

Biogen is bulking up in immunology—and paving the way for its nephrology future—with an M&A play that adds two ongoing launches to its marketed lineup.

Fraiser Kansteiner Mar 31, 2026 10:32am

Biogen looks to shake up SMA status quo with Spinraza HD nod

Mar 30, 2026 9:58am

Biogen ticks up sales outlook again as MS franchise holds strong

Oct 30, 2025 1:37pm

As new launches take flight, 'a new Biogen' emerges, CEO says

May 1, 2025 11:55am

Biogen places chips behind 4 new drugs as MS competition mounts

Feb 12, 2025 11:35am

Biogen raises profit guidance as Leqembi's launch trudges on

Oct 30, 2024 12:30pm